The current COVID-19 pandemic has created yet another healthcare issue, with the emergence of a fungal disease that has resulted in a higher fatality rate. COVID-19 patients are predisposed to fungal infections such as mucormycosis, which has been reported in patients who are currently battling and those who have recently recovered, particularly those who are medically compromised. There has been a recent increase in the incidence of rhino--maxillary mucormycosis, which has become an emerging problem. We report cases of rhino-maxillary mucormycosis presenting with early oral manifestations to help in early diagnosis and treatment.
Methods: We retrospectively investigated fourteen cases of rhino-maxillary mucormycosis presenting initially with oral findings in post-COVID-19 diabetic patients who reported to the Department of Dental surgery, Andhra Medical College, Visakhapatnam, India.
Statistical analysis: The data were analyzed for age distribution, gender variation, presence of particular clinical signs and symptoms, and correlation of clinical and histopathological and radiological findings. Using statistical software SPSS V2, the Student t-test and chi-square test were applied to the data. P-value equal to or less than 0.05 is considered statistically significant (P
Key words: Mucormycosis, COVID 19, fungal infection, immunocompromised patients
|
